Ozempic Is About to Go Generic in India, China and Canada
In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions.
Read Full Story
Advertise Here contact ads[@]ghheadlines.com
Related Items
Drugs (Pharmaceuticals)
Weight
Obesity
GLP-1 RAs (Drug)
Prices (Fares
Fees and Rates)
Generic Brands and Products
Regulation and Deregulation of Industry
Ozempic (Drug)
Developing Countries
Diabetes
Eli Lilly and Company
Novo Nordisk A/S
Africa
China
Delhi (India)
Hong Kong
India
Canada

Facebook
Twitter
Pinterest
Instagram
Google+
YouTube
LinkedIn
RSS